Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy.
The post Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’ appeared first on MedCity News.
